Novo Holdings set to win EU nod for $16.5 bln Catalent deal, source says
Adds the European Commission declines comment, Novo and Catalent did not immediately respond to request for comments, details
By Foo Yun Chee and Maggie Fick
BRUSSELS/LONDON, Nov 22 (Reuters) -Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug makerCatalent CTLT.N, a person with direct knowledge of the matter said on Friday, clearing a key hurdle.
Another source said Catalent is preparing senior management for the deal to go through.
Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk NOVOb.CO, whose profit from blockbuster weight-loss drug Wegovy has made it Europe's most valuable company by market value.
The deal would help Novo Nordisk boost output of Wegovy, a once-weekly injection.
The European Commission, which acts as the EU competition watchdog and has set a Dec. 6 deadline for its decision, declined to comment.
Novo Holdings, Novo Nordisk and Catalent did not immediately respond to requests for comment.
In May, the companies said they had received a second request from the U.S. Federal Trade Commission (FTC) for more information on the deal. However, there has been no update from the U.S. antitrust agency since then.
Reporting by Foo Yun Chee in Brussels and Maggie Fick in London; Editing by Louise Heavens
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
